CHICAGO: Cryport Inc. announced that its validated cryogenic logistics solution is supporting the worldwide distribution of Stemedica’s ischemic-tolerant stem cell product lines.
Stemedica Cell Technologies, Inc. develops and manufactures best-in-class ischemic-tolerant stem cell products and biological products. Stemedica’s line of stem cell products support preclinical and clinical studies conducted by clinical research institutions and accredited hospitals.
Its mesenchymal stem cells (“MSCs”), derived from adult bone marrow, and allogeneic neural stem cells (“NSCs”), taken from donated brain tissue, have received multiple Investigational New Drug (“IND”) designations and are FDA-approved for clinical trials involving the treatment of stroke, chronic heart failure, cutaneous photoaging and Alzheimer’s disease.